Figitumumab (CP-751,871) for cancer therapy

Insulin-like growth factor-I receptor signal transduction and the Janus Kinase/Signal Transducer and Activator of Transcription (JAK-STAT) pathway

(2009) Eddy Himpe et al.   BIOFACTORS

Safety, tolerability, and pharmacokinetics of the anti-IGF-1R monoclonal antibody figitumumab in patients with refractory adrenocortical carcinoma

(2009) Paul Haluska et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Expression of Insulin Receptor Isoform A and Insulin-like Growth Factor-1 Receptor in Human Acute Myelogenous Leukemia: Effect of the Dual-Receptor Inhibitor BMS-536924 In vitro

(2009) A. E. Wahner Hendrickson et al.   CANCER RESEARCH

The Insulin-like Growth Factor-1 Receptor-Targeting Antibody, CP-751,871, Suppresses Tumor-Derived VEGF and Synergizes with Rapamycin in Models of Childhood Sarcoma

(2009) R. T. Kurmasheva et al.   CANCER RESEARCH

Inhibition of Insulin-Like Growth Factor 1 Receptor by CP-751,871 Radiosensitizes Non-Small Cell Lung Cancer Cells

(2009) T. Iwasa et al.   CLINICAL CANCER RESEARCH

Development of the Monoclonal Antibody Figitumumab, Targeting the Insulin-like Growth Factor-1 Receptor, for the Treatment of Patients with Non–Small-Cell Lung Cancer

(2009) Antonio Gualberto et al.   Clinical Lung Cancer

Clinical Development of Inhibitors of the Insulin-like Growth Factor Receptor in Oncology

(2009) Antonio Gualberto et al.   CURRENT DRUG TARGETS

1006 The anti-IGF-IR antibody figitumumab (CP-751,871) is active in patients with lung adenocarcinoma undergoing epithelial-tomesenchymal transition

(2009) A. Gualberto et al.   EJC SUPPLEMENTS

Gastrosplenic Fistula From Hodgkin's Lymphoma

(2009) Carolyn D. Seib et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase II Study of the Anti–Insulin-Like Growth Factor Type 1 Receptor Antibody CP-751,871 in Combination With Paclitaxel and Carboplatin in Previously Untreated, Locally Advanced, or Metastatic Non–Small-Cell Lung Cancer

(2009) Daniel D. Karp et al.   JOURNAL OF CLINICAL ONCOLOGY

Safety, Pharmacokinetics, and Pharmacodynamics of the Insulin-Like Growth Factor Type 1 Receptor Inhibitor Figitumumab (CP-751,871) in Combination with Paclitaxel and Carboplatin

(2009) Daniel D. Karp et al.   Journal of Thoracic Oncology

Safety, pharmacokinetics, and preliminary activity of the anti-IGF-1R antibody figitumumab (CP-751,871) in patients with sarcoma and Ewing's sarcoma: a phase 1 expansion cohort study

(2009) David Olmos et al.   LANCET ONCOLOGY

A Role for the CHC22 Clathrin Heavy-Chain Isoform in Human Glucose Metabolism

(2009) S. Vassilopoulos et al.   SCIENCE

Phosphorylated Insulin-Like Growth Factor-I/Insulin Receptor Is Present in All Breast Cancer Subtypes and Is Related to Poor Survival

(2008) J. H. Law et al.   CANCER RESEARCH

The Type 1 Insulin-Like Growth Factor Receptor Pathway

(2008) M. M. Chitnis et al.   CLINICAL CANCER RESEARCH

Targeting the type 1 insulin-like growth factor receptor as a treatment for cancer

(2008) John SP Yuen et al.   EXPERT OPINION ON THERAPEUTIC TARGETS

Phase I, Pharmacokinetic and Pharmacodynamic Study of the Anti–Insulinlike Growth Factor Type 1 Receptor Monoclonal Antibody CP-751,871 in Patients With Multiple Myeloma

(2008) Martha Q. Lacy et al.   JOURNAL OF CLINICAL ONCOLOGY

Insulin, the Insulin-Like Growth Factor Axis, and Mortality in Patients With Nonmetastatic Colorectal Cancer

(2008) Brian M. Wolpin et al.   JOURNAL OF CLINICAL ONCOLOGY

Evolution of the Insulin Receptor Family and Receptor Isoform Expression in Vertebrates

(2008) C. Hernandez-Sanchez et al.   MOLECULAR BIOLOGY AND EVOLUTION

Functionally significant insulin-like growth factor I receptor mutations in centenarians

(2008) Y. Suh et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Insulin receptor expression by human prostate cancers

(2008) Michael E. Cox et al.   PROSTATE

The role of IGF-I and its binding proteins in the development of type 2 diabetes and cardiovascular disease

(2007) Vivienne A. Ezzat et al.   DIABETES OBESITY & METABOLISM

Just Say Die

(2007) Scott R. Berry   JOURNAL OF CLINICAL ONCOLOGY